The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility features 2,176 high-performance GPUs across the US and Europe
Subscribe To Our Newsletter & Stay Updated
